Hjem

Leukemi

Diett: Periodisk faste bør vurderes ved de fleste tilfeller av leukemi. Man bør og vurdere å holde seg borte fra aminosyren methionine, da denne ser ut til å være en vekstfaktor for ondartede stam-celler. Den finnes rikelig i kjøtt, solsikkefrø, brie, parmesan, cheddar, tørrmelk og egg.

  • Avemar/Fermentert hvetekim
  • A-vitamin
  • Brake fern
  • Cannabisekstrakt
  • Curcumin
  • Disulfiram (L)
  • Druekjerneekstrakt
  • EGCG
  • Genistein  (N)
  • Hoxsey formula (G)
  • Low dose naltrexone (N) (R)
  • Logwood
  • Melatonin
  • Olivenblad tea
  • Parthenolide
  • Poke root tea  (G)
  • Resveratrol
  • Sodium Selenite

 

 

Akutt myelogen

  • Brake fern
  • Desloratadine
  • Dipyridamole (L)
  • EGCG
  • Feverfew (Parthenolide)
  • Fluconazole
  • Flarin
  • Ivosidenib (IDH1 hemmer)
  • Olivenblad tea/ekstrakt
  • Pau d`arco
  • Ribavirin (L)
  • Tanniner og garvesyrer
  • Valproate (L)

 

 

Kronisk myelogen

  • Artemether
  • Indirubin/Danggui Longhui Wan
  • Low dose naltrexone  (N) (R)

 

 

Kronisk lymfatisk

  • Artemisinin
  • Curcumin
  • EGCG
  • Feverfew (Parthenolide)
  • Genistein
  • Low dose naltrexone (N) (R)
  • Verapamil
  • Vitamin D

 


 

Kilder

  1. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 2009 Jul 9;114(2):257-60. Epub 2009 May 11. We tested the clinical efficacy of targeting eIF4E in M4/M5 AML patients with a physical mimic of the m(7)G cap, ribavirin. Among 11 evaluable patients there were 1 complete remission (CR), 2 partial remissions (PRs), 2 blast responses (BRs), 4 stable diseases (SDs), and 2 progressive diseases (PDs). Ribavirin-induced relocalization of nuclear eIF4E to the cytoplasm and reduction of eIF4E levels were associated with clinical response.
  2. Selenite is a potent cytotoxic agent for human primary AML cells. Cancer Lett. 2009 Sep 8;282(1):116-23. Epub 2009 Apr 3. Exposure to selenite also resulted in an increased mRNA expression of the antioxidant proteins TrxR1 and Grx, while staining for TrxR1 showed decreased protein levels. The results strongly suggest a great potential for selenite in the treatment of multi drug resistant AML.
  3. Vitamin E and N-Acetylcysteine as Antioxidant Adjuvant Therapy in Children with Acute Lymphoblastic Leukemia.Hematology/Oncology Unit, Mansoura University Children’s Hospital, Faculty of Medicine, Mansoura University, 35516 Mansoura, Egypt. We can conclude that vitamin E and NAC have been shown to be effective as antioxidant adjuvant therapy in children with ALL to reduce chemo-/radiotherapy-related toxicities during the initial period of treatment.
  4. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia (CLL). Blood. 2010 Nov 3. In the Mayo Clinic study, published online in the journal Blood, the researchers found that patients with insufficient levels of vitamin D when their leukemia was diagnosed progressed much faster and were about twice as likely to die as were patients with adequate levels of vitamin D. They also found solid trends: increasing vitamin D levels across patients matched longer survival times and decreasing levels matched shortening intervals between diagnosis and cancer progression. The association also remained after controlling for other prognostic factors associated with leukemia progression.
  5. Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia. Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):117-25.
  6. The Effect of Curcumin (as Meriva) on Absolute Lymphocyte Count (ALC), NK Cells and T Cell Populations in Patients with Stage 0/1 Chronic Lymphocytic Leukemia.Journal of Cancer Therapy Vol.06 No.07(2015), Article ID:57875,5 pages. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res. 2006 Jun;30(6):707-12. Epub 2005 Dec 1. Several patients presented here had documented steady clinical, laboratory, and/or radiographic evidence of progression immediately prior to initiation of over-the-counter green tea products and then developed objective responses shortly after self-initiating this therapy. Such anecdotes highlight the need for clinical trials of tea polyphenols to define the optimal dosing, schedule, toxicities, and clinical efficacy before widespread use can be recommended. An NCI sponsored phase I/II trial of de-caffeinated green tea extracts for patients with asymptomatic, early stage CLL opened at Mayo Clinic in August 2005.
  7. A randomized controlled, double-blind pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer. 2010 January 15; 116(2): 506–513. In children with ALL with liver toxicity, MT was associated with a trend towards significant reductions in liver toxicity. MT does not antagonize the effects of chemotherapy agents used for the treatment of ALL. Future study is needed to determine the most effective dose and duration of MT and its effect on hepatotoxicity and leukemia-free survival.
  8. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386-2398
  9. Green Tea Extract Appears to Keep Cancer in Check in Majority of CLL Patients. Using the highest dose tested in the phase I study, the researchers launched their phase II clinical trial in an additional 36 patients. The results presented at the ASCO meeting evaluate the effects in these 36 patients as well as the six patients from the phase I trial treated at the same dose (total 42 patients). Results from 41 patients who have completed the study show that 31 percent of patients had a 20 percent or greater sustained reduction in blood leukemia count, and 69 percent of patients with enlarged lymph nodes saw a reduction of node size of 50 percent or greater. In all, 69 percent of CLL patients had a biological response to EGCG as evidenced by a 20 percent or greater sustained reduction in blood lymphocyte count and/or a 50 percent or greater reduction in lymph node size, the researchers say.
  10. Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter, Integr Med (Encinitas). 2018 Feb;17(1):51-56.
  11. A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment With Epigallocatechin-3-gallate, an Extract of Green Tea. Cureus. 2015 Dec 29;7(12):e441.
  12. Clinical Effects of Oral Green Tea Extracts in Four Patients With Low Grade B-cell Malignancies. Leuk Res. 2006 Jun;30(6):707-12.
  13. A Phase 1 Trial of Daily Oral Green Tea Extract in Asymptomatic, Rai Stage 0–II Patients with Chronic Lymphocytic Leukemia. Blood (2007) 110 (11): 2047.
  14. Phase 2 Trial of Daily, Oral Polyphenon E in Patients with Asymptomatic, Rai Stage 0-II Chronic Lymphocytic Leukemia(CLL). Cancer. 2013 Jan 15; 119(2): 363–370.
  15. Verapamil Inhibits B-cell Proliferation and Tumor Necrosis Factor Release and Induces a Clinical Response in B-cell Chronic Lymphocytic Leukemia. Leukemia. 1994 Dec;8(12):2214-6.